سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Köse, Duygu, Köse, Ahmet, Halıcı, Zekai, Çadirci, Elif, Tavaci, Taha, Gürbüz, Muhammed, Maman, Adem. (1400). Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis. , 24(7), 922-927. doi: 10.22038/ijbms.2021.54152.12172
Duygu Köse; Ahmet Köse; Zekai Halıcı; Elif Çadirci; Taha Tavaci; Muhammed Ali Gürbüz; Adem Maman. "Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis". , 24, 7, 1400, 922-927. doi: 10.22038/ijbms.2021.54152.12172
Köse, Duygu, Köse, Ahmet, Halıcı, Zekai, Çadirci, Elif, Tavaci, Taha, Gürbüz, Muhammed, Maman, Adem. (1400). 'Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis', , 24(7), pp. 922-927. doi: 10.22038/ijbms.2021.54152.12172
Köse, Duygu, Köse, Ahmet, Halıcı, Zekai, Çadirci, Elif, Tavaci, Taha, Gürbüz, Muhammed, Maman, Adem. Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis. , 1400; 24(7): 922-927. doi: 10.22038/ijbms.2021.54152.12172

Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis

Iranian Journal of Basic Medical Sciences
مقاله 8، دوره 24، شماره 7، مهر 2021، صفحه 922-927    اصل مقاله (616.31 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2021.54152.12172
نویسندگان
Duygu Köse1؛ Ahmet Köse* 2؛ Zekai Halıcı3؛ Elif Çadirci4؛ Taha Tavaci5؛ Muhammed Ali Gürbüz6؛ Adem Maman7
1Clinical Research, Development and Design Application, and Research Center, Ataturk University, Erzurum, Turkey, 905074704150
2University of Health Sciences, Faculty of Medicine, Department of Orthopedics And Traumatology, Erzurum, Turkey, 905066330520
3Clinical Research, Development and Design Application and Research Center, Ataturk University, Erzurum, Turkey, 905323868884
4Faculty of Medicine, Department of Pharmacology, Atatürk University, Erzurum, Turkey, 905362328001
5Faculty of Medicine, Department of Pharmacology, Atatürk University, Erzurum, Turkey, 9005059177816
6Faculty of Medicine, Department of Histology And Embryology Department, Atatürk University, Erzurum, Turkey, 905522265686
7Faculty of Medicine, Department of Nuclear Medicine, Atatürk University, Erzurum, Turkey, 905063661925
چکیده
Objective(s): We examined the antiosteoporotic effect of bosentan (Bose) by radiographic, histopathological, and molecular methods.
Materials and Methods: Rats were divided into 4 groups of 8 rats each: one control (Sham), one osteoporosis only (OP), and two osteoporosis groups treated with Bose doses of 50 and 100 mg/kg (OP+Bose50, OP+Bose100). Six weeks later, Bose was administered for eight weeks to animals undergoing ovariectomy. The left femoral bone of the rats was evaluated in vitro after surgical removal. Bone mineral density (BMD) was analyzed by Dual-energy X-ray absorptiometry (DEXA). Endothelin 1 (ET-1), ET-A, and ET-B expressions were examined by real-time polymerase chain reaction (real time-PCR). In addition, bone tissue was evaluated histopathologically.
Results: Compared with the osteoporosıs group, Bose significantly increased BMD values at both 50 and 100 mg/kg doses. ET-1 mRNA levels were significantly higher in the OP group than in the Sham group, while ET-1 mRNA levels were significantly lower in Bose treatment groups. ET-A mRNA levels were significantly lower in the OP group than in the Sham group, while ET-A mRNA levels were significantly higher in Bose treatment groups. Histopathological results supported the molecular results.
Conclusion: Our study is the first to demonstrate the molecular, radiological, and histopathological effects of Bose in preventing osteoporosis in rats.
کلیدواژه‌ها
Bone؛ Bosentan؛ Endothelin؛ Endothelin A receptor؛ Osteoporosis
مراجع
1. Ahmed SF, Elmantaser M. Secondary osteoporosis. Endocr Dev 2009;16:170-190.
2. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544-564.
3. Turner CH, Roeder RK, Wieczorek A, Foroud T, Liu G, Peacock M. Variability in skeletal mass, structure, and biomechanical properties among inbred strains of rats. J Bone Miner Res 2001;16:1532-1539.
4. Jee WS, Yao W. Overview: Animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 2001;1:193-207.
5. Liu XL, Li CL, Lu WW, Cai WX, Zheng LW. Skeletal site-specific response to ovariectomy in a rat model: Change in bone density and microarchitecture. Clin Oral Implants Res 2015;26:392-398.
6. Bagi CM, Ammann P, Rizzoli R, Miller SC. Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 1997;61:336-344.
7. Wronski TJ, Schenck PA, Cintron M, Walsh CC. Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 1987;40:155-159.
8. Li M, Shen Y, Wronski TJ. Time course of femoral neck osteopenia in ovariectomized rats. Bone 1997;20:55-61.
9. Laib A, Kumer JL, Majumdar S, Lane NE. The temporal changes of trabecular architecture in ovariectomized rats assessed by MicroCT. Osteoporos Int 2001;12:936-941.
10. Osterhoff G, Morgan EF, Shefelbine SJ, Karim L, McNamara LM, Augat P. Bone mechanical properties and changes with osteoporosis. Injury 2016;47:S11-20.
11. Lee CY, Huang TJ, Wu MH, Li YY, Lee KD. High expression of acid-sensing ion channel 2 (ASIC2) in bone cells in osteoporotic vertebral fractures. Biomed Res Int 2019;2019:4714279.
12. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
13. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-1748.
14. Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, et al. Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA 1989;86:7634-7638.
15. Resink TJ, Scott-Burden T, Buhler FR. Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur J Biochem 1990;189:415-421.
16. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun 1993;191:823-830.
17. Chang JM, Kuo MC, Chen HM, Lee CH, Lai YH, Chen HC, et al. Endothelin-1 regulates parathyroid hormone expression of human parathyroid cells. Clin Nephrol 2006;66:25-31.
18. Tatrai A, Foster S, Lakatos P, Shankar G, Stern PH. Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures. Endocrinology 1992;131:603-607.
19. Gulhan I, Kebapcilar L, Alacacioglu A, Bilgili S, Kume T, Aytac B, et al. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol 2009;25:674-678.
20. Mestek ML, Weil BR, Greiner JJ, Westby CM, DeSouza CA, Stauffer BL. Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women. Bone 2010;47:542-545.
21. Stern PH, Tatrai A, Semler DE, Lee SK, Lakatos P, Strieleman PJ, et al. Endothelin receptors, second messengers, and actions in bone. J Nutr 1995;125:2028-2032.
22. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN. Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003;33:673-684.
23. Zhong X, Wang H, Huang S. Endothelin-1 induces interleukin-18 expression in human osteoblasts. Arch Oral Biol 2014;59:289-296.
24. Aydin A, Halici Z, Albayrak A, Polat B, Karakus E, Yildirim OS, et al. Treatment with carnitine enhances bone fracture healing under osteoporotic and/or inflammatory conditions. Basic Clin Pharmacol Toxicol 2015;117:173-179.
25. Huo MH, Troiano NW, Pelker RR, Gundberg CM, Friedlaender GE. The influence of ibuprofen on fracture repair: Biomechanical, biochemical, histologic, and histomorphometric parameters in rats. J Orthop Res 1991;9:383-390.
26. Ugan RA, Cadirci E, Halici Z, Toktay E, Cinar I. The role of urotensin-II and its receptors in sepsis-induced lung injury under diabetic conditions. Eur J Pharmacol 2018;818:457-469.
27. Nian H, Ma MH, Nian SS, Xu LL. Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 2009;16:320-326.
28. Oliver RA, Yu Y, Yee G, Low AK, Diwan AD, Walsh WR. Poor histological healing of a femoral fracture following 12 months of oestrogen deficiency in rats. Osteoporos Int 2013;24:2581-2589.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
30. Kasperk CH, Borcsok I, Schairer HU, Schneider U, Nawroth PP, Niethard FU, et al. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 1997;60:368-374.
31. Sun L, Su J, Wang M. Changes of serum IGF-1 and ET-1 levels in patients with osteoporosis and its clinical significance. Pak J Med Sci 2019;35:691-695.
32. Gulhan I, Kebapcilar L, Alacacioglu A, Bilgili S, Kume T, Aytac B, et al. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol 2009;25:674-678.
33. Aydin A, Halici Z, Akpinar E, Aksakal AM, Saritemur M, Yayla M, et al. What is the role of bosentan in healing of femur fractures in a rat model? J Bone Miner Metab 2015;33:496-506.

آمار
تعداد مشاهده مقاله: 962
تعداد دریافت فایل اصل مقاله: 409